Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|August 10, 2007
IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survivalInbal Binsky, Michal Haran, Diana Starlets, et al.
Haematologica|February 10, 2015
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experienceYair Herishanu, Neta Goldschmidt, Osnat Bairey, et al.
American Journal of Hematology|June 19, 2019
Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter studyChava Perry, Sharon Ben Barouch, Neta Goldschmidt, et al.
European Journal of Haematology|June 28, 2018
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trialsErel Joffe, Neta Goldschmidt, Osnat Bairey, et al.
Hematological Oncology|June 23, 2017
Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survivalErel Joffe, N Ariela Arad, Osnat Bairey, et al.
Cancer|February 21, 2013
Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implicationsTamar Tadmor, Lev Shvidel, Ariel Aviv, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 6, 2011
The cytokine midkine and its receptor RPTPζ regulate B cell survival in a pathway induced by CD74Sivan Cohen, Or-yam Shoshana, Einat Zelman-Toister, et al.
Anticancer Research|November 7, 2018
Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in IsraelMichal Inbar, Yair Herishanu, Neta Goldschmidt, et al.
European Journal of Haematology|July 7, 2019
A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chainTamar Tadmor, Andrei Braester, Dally Najib, et al.
Leukemia Research|June 2, 2019
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemiaTamar Tadmor, Ilana Levy, Yair Herishanu, et al.
Pageof 6